Company intelligence / Profile preview

Ixcela

Bedford, Massachusetts, United Statesixcela.com ↗

Ownership: Private
Development stage: Commercial

Overview

Ixcela offers a proprietary pinprick blood test that analyzes key small-molecule metabolites related to the gut microbiome. The results inform personalized nutrition and supplement plans designed to restore internal biochemical balance. Clinical pilots have shown improved well-being in cancer patients using their approach as an adjunct to standard care. No traditional clinical trial data for therapeutics.

Therapeutic areas: GastroenterologyMetabolic DisordersOncologyNeurology
Modalities: Device (diagnostic blood test)Dietary supplementPersonalized nutrition plan
Industry: Metabolite Diagnostics

Partnerships

Roper St. Francis Healthcare – partnership for cancer patient nutrition guidance

Beyond the preview

Go deeper on Ixcela.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ixcela.

Explore the full profile